Phase III clinical trial - Gynécologie - Ovaires

OReO
Gynécologie - Ovaires
Ouvert depuis le: 07.09.2020
Site: Paris
Ouvert depuis le: 02.14.2018
Site: Saint-Cloud
Public cible
Adulte
A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy.
Description de l'essai

The OReO study will be a Phase IIIb, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy and tolerability of Olaparib retreatment, versus matching placebo, in non-mucinous epithelial ovarian cancer (EOC) patients (including patients with primary peritoneal and/or fallopian tube cancer).